

IFW



CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED  
WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT POSTAGE  
AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO:  
COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450,  
ON 20 SEPTEMBER 2004

Deborah L. Hecht  
NAME OF PERSON MAILING DOCUMENT

9/20/04  
DATE

Attorney Docket No. PU60053

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicant: Bam, *et al.* 20 September 2004  
Serial No.: 10/823,964 Group Art Unit No.: Unknown  
Filed: 14 April 2004 Examiner: Unknown  
For: Conjugates Comprising Human IL-18 and Substitution Mutants Thereof  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

FILING OF AN INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(b)

The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 in order to comply with the duty of disclosure. Their inclusion herein should not, however, be construed as an admission that any particular cited reference is effective prior art or that it discloses or renders obvious any aspect of the claimed invention. A copy of each cited reference is enclosed, except for those references which are already part of the filewrapper. This statement is being filed within the time period specified in 37 CFR §1.97(b). No fee is required.

Respectfully submitted,  
Elizabeth J. Hecht  
Elizabeth J. Hecht  
Attorney for Applicants  
Registration No. 48,138

GLAXOSMITHKLINE  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Phone (610) 270-5009  
Facsimile (610) 270-5090  
N:\EJH\APPLNS\PU60053\IDS Letter.doc



Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. PU60053	SERIAL NO. 10/823,964
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use several sheets if necessary)</i>		APPLICANT Bam, <i>et al.</i>	
		FILING DATE 14 April 2004	GROUP Unknown

**U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	2003171284	09/11/03	Cox, <i>et al.</i>	514	12	
	2003191056	10/09/03	Walker, <i>et al.</i>	514	12	
	2003195154	10/16/03	Walker, <i>et al.</i>	514	12	
	6,602,498	08/05/03	Xiaoming Shen	424	78.08	

**FOREIGN PATENT DOCUMENTS**

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	WO99/03887	01/28/99	PCT				
	WO2002/077218	10/03/02	PCT				
	WO2001/003737	01/18/01	PCT				
	WO2001/62827	08/30/01	PCT				
	WO2000/042175	07/20/00	PCT				
	WO2001/087925	11/22/01	PCT				
	EP0712931	05/22/96	EPO				
	EP0692536	01/17/96	EPO				
	EP0974600	09/19/01	EPO				
	EP0819757	01/21/98	EPO				
	EP0816499	01/07/98	EPO				
	EP0845530	06/03/98	EPO				
	EP0859052	08/19/98	EPO				
	EP0821005	01/28/98	EPO				
	EP0767178	04/09/97	EPO				
	EP110969A1	06/27/01	EPO				

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. PU60053	SERIAL NO. 10/823,964
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use several sheets if necessary)</i>		APPLICANT Bam, <i>et al.</i>	
		FILING DATE 14 April 2004	GROUP Unknown

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

	Pomroy, <i>et al.</i> , "Solubilization of Hydrophobic Peptides by Reversible Cysteine PEGylation," <i>Biochemical and Biophysical Research Communications</i> , <u>245</u> : 618-621 (1998).
	Albrecht, <i>et al.</i> , "Production of Soluble ScFVS with C-Terminal-Free Thiol for Site-Specific Conjugation or Stable Dimeric ScFvs on Demand," <i>Bioconjugate Chem.</i> , <u>15</u> : 16-26 (2004).
	Sato, <i>et al.</i> , "Transglutaminase-Mediated Dual and Site-Specific Incorporation of Poly(ethylene glycol) Derivatives into a Chimeric Interleukin-2," <i>Bioconjugate Chem.</i> , <u>11</u> : 502-509 (2000).
	Manjula, <i>et al.</i> , "Site-Specific PEGylation of Hemoglobin at Cys-93( $\beta$ ): Correlation between the Colligative Properties of the PEGylated Protein and the Length of the Conjugated PEG Chain," <i>Bioconjugate Chem.</i> , <u>14</u> : 464-472 (2003).
	Pettit, <i>et al.</i> , "Structure-Function Studies of Interleukin 15 using Site-specific Mutagenesis, Polyethylene Glycol Conjugation, and Homology Modeling," <i>The Journal of Biological Chemistry</i> , <u>272</u> (4): 2312-2318 (1997).
	Yang, <i>et al.</i> , "Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation," <i>Protein Engineering</i> , <u>16</u> (10): 761-770 (2003).
	Uchio, <i>et al.</i> , "Site-specific insulin conjugates with enhanced stability and extended action profile," <i>Advanced Drug Delivery Reviews</i> , <u>35</u> : 289-306 (1999).
	Stimmel, <i>et al.</i> , "Site-specific Conjugation on Serine→Cysteine Variant Monoclonal Antibodies," <i>The Journal of Biological Chemistry</i> , <u>275</u> (39): 30445-30450 (2000).
	Lee, <i>et al.</i> , "Prolonged Circulating Lives of Single-Chain Fv Proteins Conjugated with Polyethylene Glycol: A Comparison of Conjugation Chemistries and Compounds," <i>Bioconjugate Chem.</i> , <u>10</u> : 973-981 (1999).
	Cantin, <i>et al.</i> , "Polyethylene Glycol Conjugation at Cys <sup>232</sup> Prolongs the Half-Life of $\alpha$ 1 Proteinase Inhibitor," <i>American Journal of Respiratory Cell Molecular Biology</i> , <u>27</u> : 659-665 (2002).
	Andrew P. Chapman, "PEGylated antibodies and antibody fragments for improved therapy: a review," <i>Advanced Drug Delivery Reviews</i> , <u>54</u> : 531-545 (2002).
	Yoshioka, <i>et al.</i> , "Optimal site-specific PEGylation of mutant RNF- $\alpha$ improves its antitumor potency," <i>Biochemical and Biophysical Research Communications</i> , <u>315</u> : 808-814 (2004).
	Lee, <i>et al.</i> , "N-Terminal Site-Specific Mono-PEGylation of Epidermal Growth Factor," <i>Pharmaceutical Research</i> , <u>20</u> (5): 818-825 (2003).
	Clark, <i>et al.</i> , "Long-acting Growth Hormones Produced by Conjugation with Polyethylene Glycol," <i>The Journal of Biological Chemistry</i> , <u>271</u> (36): 21969-21977 (1996).
	Haruya Sato, "Enzymatic procedure for site-specific pegylation of proteins," <i>Advanced Drug Delivery Reviews</i> , <u>54</u> : 487-504 (2002).

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. PU60053	SERIAL NO. 10/823,964
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use several sheets if necessary)</i>		APPLICANT Bam, <i>et al.</i>	
		FILING DATE 14 April 2004	GROUP Unknown

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

		Hinds, <i>et al.</i> , "Effects of PEG conjugation on insulin properties," <i>Advanced Drug Delivery Reviews</i> , <u>54</u> : 505-530 (2002).
		Leong, <i>et al.</i> , "Adapting Pharmacokinetic Properties of a Humanized Anti-Interleukin-8 Antibody for Therapeutic Applications Using Site-Specific Pegylation," <i>Cytokine</i> , <u>16 (3)</u> : 106-119 (2001).
		Seely, <i>et al.</i> , "Issues encountered in the production of site-specific mono-PEGylated therapeutic proteins," <i>Polymer Preprints (American Chemical Society, Division of Polymer Chemistry)</i> , <u>38(1)</u> : 572-573 (1997).
		Zalipsky, <i>et al.</i> , "Reversible PEGylation: thiolytic regeneration of active protein from its polymer conjugates," <i>Peptides: The Wave of the Future, Proceedings of the Second International and the Seventeenth American Peptide Symposium</i> , San Diego, CA, June 9-14, 2001, pp. 953-954.
EXAMINER		DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

document1